Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $30.00 price target on the stock.

Several other brokerages have also issued reports on VYGR. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, October 11th. Wedbush decreased their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Leerink Partners started coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Buy” and an average target price of $17.43.

Voyager Therapeutics Stock Up 2.3 %

NASDAQ:VYGR opened at $6.58 on Thursday. Voyager Therapeutics has a twelve month low of $5.71 and a twelve month high of $11.72. The stock has a market cap of $357.64 million, a P/E ratio of -131.50 and a beta of 0.91. The firm’s fifty day simple moving average is $6.55 and its 200 day simple moving average is $7.64.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The firm had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. During the same quarter in the previous year, the firm posted ($0.51) EPS. On average, analysts expect that Voyager Therapeutics will post -1.27 EPS for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors have recently made changes to their positions in VYGR. Armistice Capital LLC increased its holdings in Voyager Therapeutics by 11.3% during the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after buying an additional 528,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after purchasing an additional 1,000,000 shares in the last quarter. Great Point Partners LLC bought a new position in Voyager Therapeutics in the 2nd quarter worth $12,668,000. Finally, Price T Rowe Associates Inc. MD lifted its position in Voyager Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after purchasing an additional 37,144 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.